A study on leflunomide-induced liver injury in rheumatoid arthritis patients

Salmi Abdul Razak, Farida Hanim Islahudin, Ahmad Fuad Shamsuddin, Nor Shuhaila Shahri

Research output: Contribution to journalArticle

Abstract

Leflunomide is an effective disease-modifying anti rheumatic drug with reported adverse drug reactions. This retrospective study is aimed to quantify the incidence of adverse drug reactions and predict risk factors of leflunomideinduced liver injury in the treatment regimen of rheumatoid arthritis patients. Rheumatoid arthritis patients on leflunomide treatment were identified from a local tertiary hospital. Data was retrieved for 73 patients. A total number of 35 patients were found to have elevated liver enzyme levels during treatment with leflunomide. The mean onset of liver enzyme abnormalities occurred after 6.44 ± 8.11 months from the initiation of leflunomide in rheumatoid arthritis patients' treatment regimen. Termination of disease-modifying anti rheumatic drug was found highest 15.1% (n=11) due to events of liver injury, followed by 12.3% (n=9) due to other adverse drug reactions. It has been shown that the type of rheumatoid factor (p=0.005) and dyslipidemia (p=0.029) are predictors to the incidence of liver injury based on liver enzyme abnormalities.

Original languageEnglish
Pages (from-to)556-561
Number of pages6
JournalResearch Journal of Pharmacy and Technology
Volume6
Issue number5
Publication statusPublished - 2013

Fingerprint

leflunomide
Rheumatoid Arthritis
Liver
Wounds and Injuries
Drug-Related Side Effects and Adverse Reactions
Antirheumatic Agents
Enzymes
Rheumatoid Factor
Incidence
Therapeutics
Dyslipidemias
Tertiary Care Centers
Retrospective Studies

Keywords

  • Adverse
  • Arthritis
  • Leflunomide
  • Liver
  • Rheumatoid

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

A study on leflunomide-induced liver injury in rheumatoid arthritis patients. / Razak, Salmi Abdul; Islahudin, Farida Hanim; Shamsuddin, Ahmad Fuad; Shahri, Nor Shuhaila.

In: Research Journal of Pharmacy and Technology, Vol. 6, No. 5, 2013, p. 556-561.

Research output: Contribution to journalArticle

Razak, Salmi Abdul ; Islahudin, Farida Hanim ; Shamsuddin, Ahmad Fuad ; Shahri, Nor Shuhaila. / A study on leflunomide-induced liver injury in rheumatoid arthritis patients. In: Research Journal of Pharmacy and Technology. 2013 ; Vol. 6, No. 5. pp. 556-561.
@article{ffb0cfd9ab344125a85c888f35a1ff3a,
title = "A study on leflunomide-induced liver injury in rheumatoid arthritis patients",
abstract = "Leflunomide is an effective disease-modifying anti rheumatic drug with reported adverse drug reactions. This retrospective study is aimed to quantify the incidence of adverse drug reactions and predict risk factors of leflunomideinduced liver injury in the treatment regimen of rheumatoid arthritis patients. Rheumatoid arthritis patients on leflunomide treatment were identified from a local tertiary hospital. Data was retrieved for 73 patients. A total number of 35 patients were found to have elevated liver enzyme levels during treatment with leflunomide. The mean onset of liver enzyme abnormalities occurred after 6.44 ± 8.11 months from the initiation of leflunomide in rheumatoid arthritis patients' treatment regimen. Termination of disease-modifying anti rheumatic drug was found highest 15.1{\%} (n=11) due to events of liver injury, followed by 12.3{\%} (n=9) due to other adverse drug reactions. It has been shown that the type of rheumatoid factor (p=0.005) and dyslipidemia (p=0.029) are predictors to the incidence of liver injury based on liver enzyme abnormalities.",
keywords = "Adverse, Arthritis, Leflunomide, Liver, Rheumatoid",
author = "Razak, {Salmi Abdul} and Islahudin, {Farida Hanim} and Shamsuddin, {Ahmad Fuad} and Shahri, {Nor Shuhaila}",
year = "2013",
language = "English",
volume = "6",
pages = "556--561",
journal = "Research Journal of Pharmacy and Technology",
issn = "0974-3618",
publisher = "A and V Publication",
number = "5",

}

TY - JOUR

T1 - A study on leflunomide-induced liver injury in rheumatoid arthritis patients

AU - Razak, Salmi Abdul

AU - Islahudin, Farida Hanim

AU - Shamsuddin, Ahmad Fuad

AU - Shahri, Nor Shuhaila

PY - 2013

Y1 - 2013

N2 - Leflunomide is an effective disease-modifying anti rheumatic drug with reported adverse drug reactions. This retrospective study is aimed to quantify the incidence of adverse drug reactions and predict risk factors of leflunomideinduced liver injury in the treatment regimen of rheumatoid arthritis patients. Rheumatoid arthritis patients on leflunomide treatment were identified from a local tertiary hospital. Data was retrieved for 73 patients. A total number of 35 patients were found to have elevated liver enzyme levels during treatment with leflunomide. The mean onset of liver enzyme abnormalities occurred after 6.44 ± 8.11 months from the initiation of leflunomide in rheumatoid arthritis patients' treatment regimen. Termination of disease-modifying anti rheumatic drug was found highest 15.1% (n=11) due to events of liver injury, followed by 12.3% (n=9) due to other adverse drug reactions. It has been shown that the type of rheumatoid factor (p=0.005) and dyslipidemia (p=0.029) are predictors to the incidence of liver injury based on liver enzyme abnormalities.

AB - Leflunomide is an effective disease-modifying anti rheumatic drug with reported adverse drug reactions. This retrospective study is aimed to quantify the incidence of adverse drug reactions and predict risk factors of leflunomideinduced liver injury in the treatment regimen of rheumatoid arthritis patients. Rheumatoid arthritis patients on leflunomide treatment were identified from a local tertiary hospital. Data was retrieved for 73 patients. A total number of 35 patients were found to have elevated liver enzyme levels during treatment with leflunomide. The mean onset of liver enzyme abnormalities occurred after 6.44 ± 8.11 months from the initiation of leflunomide in rheumatoid arthritis patients' treatment regimen. Termination of disease-modifying anti rheumatic drug was found highest 15.1% (n=11) due to events of liver injury, followed by 12.3% (n=9) due to other adverse drug reactions. It has been shown that the type of rheumatoid factor (p=0.005) and dyslipidemia (p=0.029) are predictors to the incidence of liver injury based on liver enzyme abnormalities.

KW - Adverse

KW - Arthritis

KW - Leflunomide

KW - Liver

KW - Rheumatoid

UR - http://www.scopus.com/inward/record.url?scp=84880812028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880812028&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84880812028

VL - 6

SP - 556

EP - 561

JO - Research Journal of Pharmacy and Technology

JF - Research Journal of Pharmacy and Technology

SN - 0974-3618

IS - 5

ER -